Novo’s obesity drug has serious warnings and barriers to overcome
World of DTC Marketing
JUNE 6, 2021
The headlines read “FDA approves obesity drug that helped people cut weight 15%” But buyer beware. Wegovy also contains warnings for pancreatitis, gallbladder problems including gallstones, low blood sugar, acute kidney injury, eye retina damage, increased heart rate, and suicidal behavior or thinking.
Let's personalize your content